Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG) Receives Buy Rating

1964

By Mark Michaels on July 2, 2014 BioPharma

TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) is a pharmaceutical company that aims at discovering latest molecular medicines and drugs for the treatment of cancerous and infectious cells in the body. Once discovered, the company focuses on developing those drugs in order to cause the abnormal cancerous and infectious cells of the body to self-destruct themselves. The company is a clinical-stage pharmaceutical with its Brinipant, a drug designed for tumor patients, being tested for phase 1 and phase 2 trials. More than 275 subjects have been enrolled for this trial alone.

Nomura Holdings, a Japanese financial holding company and a prime member of Nomura Group, conducted its research on the Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG), on Thursday. The analyst firm was of the opinion that the Company was well suited to be put in the ‘buy’ category. Moreover, Nomura Holdings gave the company a target price of $9 on its stocks. If the current target price set by Nomura Holdings is compared with the previous closing price, an escalation of 64.53% will be seen.

For the last trading session, Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG)’s highest share price hit the figures of $14.75 whereas the lowest share price was recorded to be at $3.84. Not only that, but the company stood strong in the pharmaceutical industry with a market cap of around $121.7 million shares. As far as the 50-day and 200-day average share prices of Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG) are concerned, the company was successful in keeping them at $5.03 and $7.37 respectively. Moreover, on Thursday, the shares of the company were opened at quite an average rate of $5.47 per share.

Talking about Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG), Nomura was not the only financial company who ran a research on the company’s profile and stock information, a lot of other market analyst firms have also conducted their research on Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG) during the same time period. The most prominent name among those market analyst firms is Guggenheim Securities, which is a branch of Guggenheim Partners; this firm is yet another of the world-class advisory and analyst firms for stock transactions. A senior analyst at Guggenheim in his research report, on May 9, 2014 (Friday), set the target price of Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG) at $13 whereas, previously, the target price was set at $15.

Moreover, WBB Securities, a leading company in the equity research and investment management, ran its analysis on Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG) on the 9^th of April, 2014 (Wednesday). According to its market analysis report, the target price of the company has gone up to the value of $15.50, where previously, the target price was set at $12. WBB Securities also changed the status of Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG)’s shares to ‘buy’ from a ‘speculative buy’.

Not only that, but four other analyst firms have given Tetralogic Pharmaceuticals Corporation (NASDAQ:TLOG) a positive rating of buy. With that, the company’s overall rating is set to be at ‘buy’ with an average target price of $12.50.